Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
MAbSilico logo — The only TechBio providing computationally designed antibodi...

MAbSilico

The only TechBio providing computationally designed antibodies through AI with biological validations associated

Founded 2017 France France 14 employees Total: $1.50M AI, Biotechnology +4

General Information

Company Name MAbSilico
Founded Year 2017
Location France France
Employees 14
Industries AI, Biotechnology, Health Care +3
Business Model B2B, On Demand, Platform
Revenue Model Project Based, Licensing, Service Fee
Offices as of Nov 2026
Tours, France Paris, France
Social

BounceWatch is an independent company data service, not affiliated with MAbSilico. To contact MAbSilico, visit mabsilico.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does MAbSilico compare?

A PDF of MAbSilico and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting MAbSilico soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Nov 05, 2026

MAbSilico's Zak is representing the company at the ACTIP Meeting in Germany to introduce a new AI developability assessment service.

New Partnership Oct 23, 2026

MAbSilico announced a partnership with Sartorius to accelerate therapeutic protein target identification and drug discovery.

MAbSilico a competitor of yours? Have our desk watch it

About MAbSilico

MAbSilico is a pioneering TechBio company, founded in 2017, headquartered in France. It specializes in leveraging AI and machine learning for the computational design of antibodies, positioning itself at the intersection of biotechnology, health care, life sciences, and pharmaceuticals. The company's slogan, "The only TechBio providing computationally designed antibodies through AI with biological validations associated," underscores its unique approach of combining in silico technology with biological validation.

MAbSilico addresses the critical need for rapid and reliable antibody drug discovery by analyzing epitope, affinity, and off-target risks to quickly provide biotech and pharmaceutical companies with viable antibody candidates. In its recent financial developments, MAbSilico secured a €500.00K grant investment on 01 January 2023, backed by notable investors such as Bpifrance and Région Centre-Val de Loire, reinforcing confidence in its innovative approach and growth potential.

Business keywords: TechBio, AI-based solutions, Antibody drug design, Computational antibody design, Biological validation, 3D modeling, Interaction simulation, Epitope mapping, Affymetrix management, Cross-species reactivity, Developability assessment, NLP in biotechnology, Freedom to operate analysis, Protein interaction, In silico antibody development

Services & Products

AI-based solutions for therapeutic antibody discovery
Design and development of high-affinity, epitope-specific antibodies
Optimization of antibody manufacturability and stability
Evaluation of cross-reactivity and cross-specificity for pre-clinical development

Target Customers

Biotechnology companies Pharmaceutical companies Research institutions Drug discovery program managers

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €500.00K 2
Bpifrance
Bpifrance, Région Centre-Val de Loire
01 Jan 2023
Grant €1.00M 2
Bpifrance
Bpifrance, INOV
01 Jun 2020
Support Program Undisclosed 1
EIT Health
01 Jan 2020
Spinout Undisclosed 3
CNRS Innovation
CNRS Innovation, French National Centre for Scientific Research - CNRS +1
01 Sep 2017

MAbSilico Alternatives & Competitors

MAbSilico vs
Circle Pharma, Inc.
Circle Pharma, Inc. United States

A New Paradigm For Macrocycle Drug Development

Series E
64 employees
Biotechnology, Health Care

FAQ About MAbSilico

The only TechBio providing computationally designed antibodies through AI with biological validations associated
MAbSilico was founded in 2017.
MAbSilico is headquartered in France. As of Nov 2026, it also has offices in Tours, France and Paris, France.
MAbSilico operates in AI, Biotechnology, Health Care, Life Sciences, Pharmaceutical and Machine Learning. Its work centres on TechBio, AI-based solutions, Antibody drug design and Computational antibody design. Its customers include Biotechnology companies, Pharmaceutical companies and Research institutions.
MAbSilico has a B2B, On Demand and Platform business model. Its revenue comes from Project Based, Licensing and Service Fee.
MAbSilico has approximately 14 employees.
MAbSilico has completed 4 funding rounds, raising a total of $1.50M.
MAbSilico offers: AI-based solutions for therapeutic antibody discovery, Design and development of high-affinity, epitope-specific antibodies, Optimization of antibody manufacturability and stability, Evaluation of cross-reactivity and cross-specificity for pre-clinical development.
Top alternatives and competitors to MAbSilico include Circle Pharma, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MAbSilico and Circle Pharma, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MAbSilico, https://bouncewatch.com/company/mabsilico, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout